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Abstract
Background: New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently
available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative
and death signaling, agents shifting the equilibrium toward the latter are of considerable interest. The TWEAK:Fn14
signaling axis promotes tumor cell proliferation and tumor angiogenesis, while TRAIL:TRAIL-receptor (TRAIL-R)
interactions selectively induce apoptosis in malignant cells. Fn14•TRAIL, a fusion protein bridging these two
pathways, has the potential to inhibit tumor growth, by interfering with TWEAK:Fn14 signaling, while at the same time
enforcing TRAIL:TRAIL-R-mediated apoptosis. Consequently, Fn14•TRAIL's capacity to inhibit HCC growth was
tested.
Results: Fn14•TRAIL induced robust apoptosis of multiple HCC cell lines, while sparing non-malignant hepatocyte
cell lines. Differential susceptibility to this agent did not correlate with expression levels of TRAIL, TRAIL-R, TWEAK
and Fn14 by these lines. Fn14•TRAIL was more potent than soluble TRAIL, soluble Fn14, or a combination of the
two. The requirement of both of Fn14•TRAIL's molecular domains for function was established using blocking
antibodies directed against each of them. Subcutaneous injection of Fn14•TRAIL abrogated HCC growth in a
xenograft model, and was well tolerated by the mice.
Conclusions: In this study, Fn14•TRAIL, a multifunctional fusion protein originally designed to treat autoimmunity,
was shown to inhibit the growth of HCC, both in vitro and in vivo. The demonstration of this fusion protein’s potent
anti-tumor activity suggests that simultaneous targeting of two signaling axes by a single fusion can serve as a basis
for highly effective anti-cancer therapies.
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Introduction
Hepatocellular cancer (HCC, hepatoma) is one of the most
common solid tumors, fifth in incidence worldwide [1]. Since
HCC is refractory to currently available chemotherapeutics,
surgical resection and liver transplantation remain the only
potential curative treatment options for a limited number of
suitable patients [2]. Thus, new and effective therapeutic
strategies for hepatoma are needed.
The net balance of positive and negative intercellular
signaling dictates tumor cell proliferation and survival, and
proteins of the tumor necrosis factor (TNF) superfamily loom
large in this array of regulatory signaling inputs [3]. TNF
superfamily proteins contribute to tissue homeostasis via
effects on cell survival, death and differentiation. In the context
of HCC and various other tumor types, two members of the
TNF superfamily may have special significance, namely, the
cell surface ligands TWEAK (TNF-related weak inducer of
apoptosis) and TRAIL (TNF-related apoptosis ligand). TWEAK
is expressed either as a type 2 membrane protein (with its
carboxy-terminus oriented extracellularly) or as a soluble ligand
by a range of cell types, including macrophage, monocytes, NK
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cells, and endothelial cells [4,5]. The counter receptor for
TWEAK, Fn14 (fibroblast growth –factor-inducible 14kD
protein), is a membrane bound type 1 protein that is also
expressed on a large variety of cells [5]. Whereas hepatocytes
do not normally express Fn14 mRNA or protein, HCC cells and
hepatocytes of regenerating liver express significant amounts
of them [6].
Intriguingly, there are reports that HCC cells that have high
levels of surface Fn14, also express TWEAK [7], in both
membrane-anchored and soluble forms. In turn, this has led to
evidence that the TWEAK:Fn14 signaling axis promotes HCC
cell proliferation through autocrine and paracrine signaling [7].
Studies with glioblastoma have indicated that TWEAK induces
pro-survival signaling by activating the NF-kB transcription
factor and upregulating the expression of the anti-apoptotic
proteins BCL-XL and BCL-W. TWEAK contributes to cancer by
other mechanisms as well, for example, via its pro-angiogenic
activity [8,9].
TRAIL binds to several different cognate TNF superfamily
receptors, some activating and others decoy. The activating
receptors in humans are TRAIL-R1 (DR4), TRAIL-R2 (DR5),
and osteoprotegrin [10,11]. There is significant cross-reactivity
between the human and mice TRAIL ligands. Importantly,
TRAIL selectively induces apoptosis in a range of transformed
cell lines, but not in normal tissues [12,13]. In the case of HCC,
there is constitutive expression of both TRAIL and its receptors
[14,15]. However, the data in the literature bearing on the
functionality of this TRAIL receptor are contradictory, with most
data indicating that HCC cells are resistant to TRAIL-induced
apoptosis. This refractoriness has suggested there may be
disturbances in the apoptotic pathway and/or over-activation of
pro-proliferative and survival signals in HCC cells [12,15].
In viewing TWEAK’s pro-proliferative and apoptosis-blockade
activities in HCC, alongside the relative refractoriness of this
tumor type to TRAIL-induced apoptosis, we posited that there
may be functional cross-talk between these TNF pathways
wherein TWEAK signaling contributes to TRAIL-resistance. In
turn, this prompted the notion that blocking TWEAK:Fn14
signaling might restore death signaling through the
TRAIL:TRAIL receptor axis in HCC cells. To test this
hypothesis, we have here turned to Fn14•TRAIL, the recently-
described fusion protein which bridges the TWEAK-Fn14 and
TRAIL-TRAIL-R signaling axes [16]. In particular, the Fn14
component of Fn14•TRAIL serves to block the binding of
endogenous TWEAK to Fn14 on HCC cells, while the TRAIL
component, once anchored to TWEAK-bearing cells or to
soluble TWEAK via the Fn14 bridge, can direct intercellular and
intra-cellular inhibitory signals to its cognate receptors on
TRAIL-receptor bearing cells. Thus, Fn14•TRAIL is in essence
converting a TWEAK pro-proliferative signal into a death-
inducing one.
In the present study, we assess Fn14•TRAIL’s ability to
induce apoptosis of HCC cell lines in vitro and inhibit their
growth as xenograft tumors in vivo. Our data establish a potent
anti-tumor effect of this fusion protein, and point to its
considerable therapeutic potential in bridging the TWEAK-Fn14
and TRAIL-TRAIL-R signaling axes.
Materials and Methods
Materials
Unless otherwise stated, all chemicals were obtained from
SIGMA (Israel). DMEM medium, FBS, PBS, Trypsin-EDTA,
penicillin, streptomycin and L-Glutamine were obtained from
Biological Industries (Beit Haemek, Israel).
Cell lines
SK-HEP-1 (HTB-52; liver adenocarcinoma cell line) was
purchased from ATCC (USA). HepG2, Huh7 and Hep3B HCC
cell lines, originally from the ATCC, were kindly provided by the
Hepatology Unit, Hadassah Hebrew University Medical Center
in Jerusalem, Israel. Immortalized human hepatocyte cell lines
FHB [17] and NKNT3 [18,19] were kindly provided by Prof.
Eithan Galun at the Hadassah Gene Therapy Institute
(Jerusalem, Israel). Cell lines were grown in 10% FBS DMEM
supplemented with penicillin, streptomycin and L-Glutamine.
The medium for FHB cells contained two additional
components: hydrocortisone (5μM) and insulin (0.85 μM).
NKNT3 cells were grown in Complete Serum-Free medium
(CS-C; Cell Systems, Kyrkland, WA, USA). All cultures were
tested periodically for mycoplasma contamination using EZ-
PCR mycoplasma test kit (Biological Industries).
Protein Production
Fn14•TRAIL was produced and purified for us by Cobra Bio-
manufacturing (Keele, UK). Chinese Hamster Ovary (CHO)
cells were stably transfected with a DNA construct encoding a
chimeric human Fn14•TRAIL sequence downstream of the
CMV promoter. A stable CHO cell transfectant clone was
isolated and expanded in serum-free medium. Fn14•TRAIL
was purified from the medium using chromatographic methods
to over 95% purity and stored at -80°C. The amino acid
sequence of the expressed Fn14•TRAIL protein is shown in
Figure 1A. The underlined sequence represents the signal-
peptide of the human Urokinase protein, utilized here to
promote secretion of Fn14•TRAIL, it is absent from the mature
protein. The amino acid sequence of the extracellular domain
of human Fn14 (amino acids 1-52 of the mature protein,
designated in bold letters) are directly linked to the extracellular
domain of human TRAIL (amino acids 53-217 of the mature
protein).
Western Blot and coomassie blue staining profiles of
Fn14•TRAIL
Fn14•TRAIL was separated on 12% SDS–PAGE, and
Coomassie blue staining was performed with GelCode blue
stain reagent (PIERCE, Rockford, IL, USA), according to
manufacturer instructions.
For western blot analysis, Fn14•TRAIL or whole cell lysate
were separated on 10% SDS-PAGE and blotted according to
standard procedures [20]. Membranes were incubated with
primary antibodies: anti-TRAIL (ALEXIS biochemicals, San
Diego, CA, USA), anti-Fn14 (ALEXIS biochemicals), anti
Caspase 3, 8 and 9, pNFkB, Bcl-2, pJNK, cIAP1, 2(Cell
Signaling), anti- IkB (R&D), and anti cFLIP (ENZO, CA, USA).
Fn14*TRAIL Inhibits HCC Growth in Xenograft Model
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Secondary immunostaining was performed with HRP-
conjugated Ab (Biorad, Hercules, CA, USA).
Activity assay
To asses Fn14•TRAIL's activity, 0.2 x 106 cells/ml (for Huh7,
0.4 x 106 cells/ml) were seeded as duplicates in 24-well plates
(NUNC, Roskilde, Denmark) and cultured with or without
varying concentrations of Fn14•TRAIL, soluble TRAIL (hTRAIL/
Apo2L; PeproTech, Rocky Hill, NJ, USA, or BioVision,
Mountain View, CA USA), Fn14-Fc (recombinant mouse;
ALEXIS Biochemicals, San Diego, CA, USA), or a combination
of the latter two. Soluble Fn14 (recombinant human Tweak
receptor, PeproTech) was used instead of Fn14-Fc in some
experiments. Cells were incubated with the indicated proteins
for 24h, 48h or 72h for harvested and stained with trypan-blue.
Live, unstained cells were counted in a grid chamber.
Quantitative Real-Time PCR Analysis
Total RNA was extracted from cell lines using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). For cDNA synthesis, 2 μg of
total RNA were reverse-transcribed using a High Capacity
cDNA Reverse Transcriptase kit (Applied Biosystems, Foster
City, CA, USA), according to manufacturer's protocol.
Quantitive real-time PCR was performed using TaqMan Assay-
on-DemandTM (TWEAK - Hs00356411_m1, Fn14 -
Hs00171993_m1, TRAIL - Hs00234355_m1, DR4 -
Hs00269492_m1, DR5 - Hs01043171_m1, DcR1 -
Hs00182570_m1, DcR2 - Hs01043162_g1, OPG -
Hs00171068_m1) and TaqMan Gene Expression Master Mix
(Applied Biosystems). All reactions were performed in
triplicates using the 7900HT Fast Real Time PCR system
(Applied Biosystems), and normalized against two endogenous
control human genes, TBP (Hs99999910_m1) and Actin-B
(Hs99999903_m1). Analysis of results was based on the
formula 2-ΔΔCt, using SDS v2.3 and data-assist v2.0 software
(Applied Biosystems).
Flow Cytometry
To assess apoptosis, 0.2 x 106 cells/ml (for Huh7, 0.4 x 106
cells/ml) were seeded as duplicates in 24-well plates and
incubated with or without varying concentrations of
Fn14•TRAIL, soluble TRAIL, Fn14-Fc or the latter two in
combination for 24 h. Apoptotic cells were detected by flow
cytometric analysis, using the AnnexinV/PI MEBCYTO
Apoptosis Kit (MBL, Nagoya Japan), according to the
manufacturer’s protocol. 20,000 events per sample were
counted using a FACSCalibur flow cytometer (Becton
Figure 1.  Molecular analysis of the Fn14•TRAIL.  (A) The amino-acid sequence of the Fn14-TRAIL protein. The amino-acid
sequence of the extra-cellular domain of human Fn14 (amino-acids 1-52 of the mature protein, marked in bold letters) are directly
linked to the extra-cellular domain of human TRAIL (amino-acids 53-217 of the mature protein, non-bold letters). The underlined
sequence represents the signal-peptide of the human Urokinase protein, utilized to secrete Fn14-TRAIL out of the cell and removed
from the mature protein. (B) Fn14-TRAIL separated at denaturizing conditions on SDS-PAGE, Coomassie gel staining. (C) Western
blot analysis with anti-TRAIL and anti-Fn14 primary antibodies.
doi: 10.1371/journal.pone.0077050.g001
Fn14*TRAIL Inhibits HCC Growth in Xenograft Model
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e77050
Dickinson, San Jose, CA, USA), and data were analyzed using
CellQuest software (Becton Dickinson).
In some experiments, Fn14•TRAIL was pre-incubated with
one of the following proteins, prior to addition to the cultures:
anti-human/mouse Fn14 (an IgA isotype Ab); anti-hTRAIL (an
IgG-1 Isotype Ab); mouse IgA and mouse IgG, with all the latter
reagents obtained from eBioscience, San Diego, CA, USA.
To examine expression of TRAIL receptors, TRAIL, Fn14
and TWEAK on cell lines, adherent cells were retrieved using
Accutase (Innovative Cell Technologies, San Diego, CA, USA),
washed, and stained with phycoerythrin-conjugated mAb
against TWEAK (CARL-1), Fn14 (ITEM-4), TRAIL (RIK-2), the
TRAIL receptors DR4 (DJR1), DR5 (DJR2-4) and DcR1
(TRAIL-R3) and DcR2 (TRAIL-R4) (R&D, Minneapolis,
Minnesota, USA) or their isotype control Abs (eBioscience).
Presence of intracellular TWEAK was determined using a
Fixation and Permeabilization Kit (eBioscience), according to
the manufacturer's protocol. Flow cytometry was performed
and analyzed as above.
Tweak ELISA
To determine TWEAK secretion to cell culture medium, cells
(105) were seeded in 24 well plates for 72h and conditioned
medium was collected and centrifuged. Clear medium was
concentrated x3 using a speed-vac centrifuge, and analyzed by
Human TWEAK ELISA development Kit (PeproTech),
according to manufacturer instructions.
Establishment of Tumor Xenografts
All experiments were approved by the Animal Care
Committee of the Hebrew University. Athymic BALB/c nu/nu
nude male mice (Harlan, Israel), 4-6 weeks of age, were
maintained under defined flora conditions at the Hebrew
University Pathogen-Free Animal Facility. HepG2 cells were
grown to 80% confluence, harvested, washed with PBS, and
injected subcutaneously (4 x 106/mouse) into the right flanks of
mice. Once palpable, tumors were measured for their widths
and lengths using a micro-caliper, and tumor volumes were
calculated (w2 x length /2). Mice were treated daily with
subcutaneous injections of Fn14•TRAIL (200 μg/mouse) for 8
days. Control groups were injected with Fn14•TRAIL dilution
buffer. At the end of experiments, mice were sacrificed, and
tumors were harvested, measured and weighed.
For liver pathology assessment, Nude mice were treated for
8 days with Fn14•TRAIL and sacrificed one hour post last
injection. Livers were removed, fixated in 4% formaldehyde,
and embedded in paraffin. Paraffin sections (5μm) were
stained with Hematoxylene and Eosin (H&E). Blood samples
were taken at day 8, one hour post Fn14•TRAIL injection.
Serum was kept at 4c. The next day, serum samples were
diluted 1:5 or more with DDW. Aspartate aminotransferase
(AST) and Alkaline phosphatase (ALK-P) serum levels were
measured by the Clinical BioChemistry Analyzer Reflotron Plus
Instrument and Starter Kit (Micglobal, Roche, London, UK),
according to the manufacturer instructions. Serum Urea levels
were determined by QuantiChromTM Urea Assay Kit
(DIUR-500), (BioAssay Systems CA, USA), according to the
manufacturer instructions.
Immunohistochemistry
To assess Fn14-TRAIL apoptosis-inducing effect in-vivo,
HepG2 tumors bearing Athymic-Nude mice were sacrificed one
hour post injection, at the 2nd injection day (200ug Fn14-TRAIL
per day). Subcutaneous tumors were removed, fixated in 4%
formaldehyde, and embedded in paraffin. Sections (5μm) were
deparaffinized in xylene (3x3') and rehydrated in graded
alcohol (3x1' 100% ethanol; 3x1' 96% ethanol). Following 5'
incubation in 3% H2O2 for endogenous peroxidase inactivation,
slides were incubated in Citrate buffer (pH6; Invitrogen) and
boiled in electric pressure cooker (BioCare Medical, CA, USA)
for antigen retrieval. Samples were blocked for 30' in CAS-
BLOCK (Invitrogen) prior to overnight incubation with the anti-
cleaved caspase 3 primary antibody (Cell Signaling #9661;
1:100 diluted in CAS-BLOCK) at 4°c in humidified box.
Following washing (3x2' in Super Sensitive wash buffer,
BioGenex), samples were incubated for 30' in RT with the
Simple stain MAX PO (MULTI) anti-rabbit immune-peroxidase
polymer (NICHIREI BIOSCIENCES INC.). Diaminobenzidine
(DAB; UltraVision Detection System, Thermo scientific, MA,
USA) was used as the chromogen according to manufacturer
instructions, and 20'' incubation in hematoxylene (SIGMA-
Aldrich) was used as the nuclear counter-stain. Following
dehydration steps (2' 80% ethanol, 2' 96% ethanol, 2' 100%
ethanol, 2' xylene) and mounting (Histomount mounting
solution, Invitrogen), x20 pictures were taken by the Nikon
ECLIPSE Ti light microscope and captured by the DSFI-1
camera (Nikon).
Statistical analysis
Data are presented as means ± SE. Statistical comparison of
means was performed by a two-tailed unpaired Student's t test.
Differences with a p<0.05 were considered statistically
significant.
Results
Fn14•TRAIL protein characterization
Fn14•TRAIL was produced as described in the materials and
methods section. Protein molecular weight, purity and identity
were verified by coommassie SDS-PAGE staining and western
blot analysis with anti Fn14 and anti TRAIL antibodies (Figure 1
B and C).
Fn14•TRAIL induces death of hepatoma cell lines
To start, we evaluated Fn14•TRAIL’s cytotoxic activity
against SK-HEP-1 hepatoma cells. As shown in Figure 2A,
Fn14•TRAIL induces death of these cells in a dose- and time-
dependent fashion. Cell death was detected at 24h and 48h,
with only about 20% of live cells detectable at 30 ng/ml
Fn14•TRAIL. Of note, significant cell death was detected at a
concentration as low as 0.1 ng/ml, corresponding to an EC50 of
0.4 nmol/l.
We extended the analysis to other hepatoma cell lines,
HepG2 and Huh7. Fn14•TRAIL exhibited a cytotoxic effect
against these tumor lines similar to that for SK-HEP-1 cells
(Figure 2B), albeit with somewhat different kinetics. In the case
Fn14*TRAIL Inhibits HCC Growth in Xenograft Model
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of Huh7, the significant cytotoxicity was apparent only after 48
h. Importantly, non-malignant hepatocyte cell lines (NKNT3 and
FHB) were resistant to death induction by Fn14•TRAIL, even at
higher concentrations (Figure 2C).
Fn14•TRAIL induces apoptosis of hepatoma cell lines
Given that TRAIL is an apoptosis-inducing ligand, we next
assessed Fn14•TRAIL’s capacity to induce apoptosis in
Figure 2.  Fn14•TRAIL induces death of HCC cell lines in a dose dependent manner.  SK-HEP-1 (A) HCC cells were incubated
with indicated concentrations of Fn14•TRAIL for 72 [left panel], 48 and 24 hours [right panel]. (B,C) HepG2 [B, left panel] and Huh7
[B, right panel] HCC cell lines, as well as NKNT3 [C, left panel] and FHB [C, right panel] hepatocyte cell lines, were incubated with
indicated concentrations of Fn14•TRAIL for 48 and 24 hours. Viable cells were stained with trypan blue and counted. Results
represent the mean +/- SE of 3 independent experiments (* p < 0.05 ** p < 0.01 vs no Fn14•TRAIL).
doi: 10.1371/journal.pone.0077050.g002
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malignant versus non-malignant hepatic cell lines using a
standard Annexin V/PI staining assay. Early (Annexin V+ only)
and late (Anexine V+ and PI+) apoptosis are summed together.
Fn14•TRAIL effectively induced apoptosis of SK-Hep1 (Figure
3A,B), HepG2 and Huh7 cell lines in a dose-dependent manner
(Figure 3B), with apoptosis apparent by the 24h time-point.
Significantly, again, minimal apoptosis was detectable in the
non-malignant cell lines treated with Fn14•TRAIL (Figure 3C).
In order to support the notion that Fn14•TRAIL's inhibitory
effect is apoptotic, caspases 3, 8, and 9 cleavage was tested
using western blots. Caspases 3 and 8 were significantly
cleaved already at short incubation periods (0.5-2 h) in the
presence of Fn14•TRAIL (Figure 3D), and at 24 h incubation
their shorter, active form appeared ( at 19 and 18 kD,
respectively, not shown). Caspase 9 was spontaneously
activated in this cell line, and therefore at earlier times no
significant change was seen with Fn14•TRAIL treatment.
(Figure 3D). Of note, experiments were repeated with all cell
lines mentioned above. Caspases activation was noted only in
HepG2, SK-HEP-1 and Huh7, while no such activation was
present in the other cell lines that did not underwent apoptosis
when incubated with Fn14•TRAIL (not shown).
We moved to look at anti-apoptotic signaling pathways.
Fn14•TRAIL was found to decrease the expression of the anti-
apoptotic proteins cFLIP and Bcl-2 (Figure 3F). Similar effects
of Fn14•TRAIL were observed when SK-HEP-1 cells were
incubated with the protein (not shown). However, in
accordance with the findings that Huh7 cells were less affected
by Fn14•TRAIL, no significant changes in cFLIP or BCL-2
expression were found after the cells were cultured in the
presence of Fn14•TRAIL for up to 24h. Interestingly, a
decrease in IκBα levels and increase in NFkB expression was
evident when cells were incubated with Fn14•TRAIL (Figure
3E). As it was previously shown that TRAIL promotes NFkB
activation [21,22], this might be related to the TRAIL side of the
molecule. No significant effect was found in cIAP1,2, JNK (total
or phosphorilated) expression when cells were incubated with
Fn14•TRAIL (not shown).
Variable amounts of TRAIL, TRAIL receptors, Fn14 and
Tweak mRNA and protein expression levels in
hepatocyte cell lines
We next wanted to test whether differences in expression
levels of TRAIL, Fn14, TWEAK, DR4, DR5, DcR1, DcR2 and
OPG can account for the different response of the various cell
lines to Fn14•TRAIL. Real time PCR analysis revealed variable
mRNA expression levels of the all examined genes (Figure
4A). Interestingly, mRNA levels were not correlated with cells'
sensitivity to Fn14•TRAIL, sTRAIL or Fn14, or with cell origin
e.g. malignant or not. Therefore, we raised the possibility that
protein expression might differ significantly between the various
cell lines resulting in the observed response to Fn14•TRAIL.
Cells in exponential growth were immunostained with
fluorescent Abs directed against DR4, DR5, DcR1, DcR2, Fn14
and TWEAK and examined by flow cytometry. All cell lines
were found to express TRAIL receptors (DR4, DR5, DcR1 and
DcR2), albeit with varying surface levels (Figure 4B, C). In
accordance with the real time PCR results, there was no
correlation between sensitivity to Fn14•TRAIL’s apoptosis-
inducing effect and the levels of surface TRAIL receptors
detected by flow cytometry. While Fn14 was also expressed on
all of these cell lines, its ligand, TWEAK, was present only at
minimally detectable levels on the cell surfaces (Figure 4B).
In order to examine TWEAK expression further, we
proceeded to assess intracellular expression of TWEAK.
Significant amounts of TWEAK were found intracellularly
(Figure 4B), but TWEAK expression level did not correlate with
cells' sensitivity.
Given the presence of TWEAK in the intracellular
compartment, we next asked if it is secreted into the medium.
To this end, cells were grown for varying time intervals up to 72
hours, and conditioned medium was analyzed by TWEAK
ELISA. Secreted TWEAK was detectable in these cell cultures
at low levels (not shown). Of note, again, no correlation was
found between TWEAK levels and sensitivity to Fn14•TRAIL.
Fn14•TRAIL binds to hepatoma cells
We next determined Fn14•TRAIL’s ability to bind to cell
surfaces. To that end, hepatoma cells were incubated in the
presence or absence of Fn14•TRAIL, at 4°C prior to
immunostaining with fluorescent-labeled anti-Fn14 Ab. All cell
lines exhibited significant Fn14 immunostaining, consistent with
Fn14•TRAIL binding to these cells (Figure 4D). This finding
suggests that the differential sensitivity of non-malignant and
malignant hepatic cell lines to Fn14•TRAIL is not simply
explained by differences in Fn14•TRAIL binding to the
respective cell types.
Fn14•TRAIL is more potent than soluble forms of TRAIL
and Fn14, alone or in combination
We next asked whether the robust efficacy of Fn14•TRAIL as
an apoptosis-inducer can be achieved by simply deploying its
component parts (Fn14 and TRAIL), alone or in combination.
To address this question, the various hepatic cell lines were
incubated in the presence or absence of either Fn14•TRAIL,
soluble TRAIL (sTRAIL), soluble Fn14 (or Fn14-Fc), or the
latter two in combination. sTRAIL is composed of 168 amino-
acids of the carboxy-terminal of the extracellular domain of
TRAIL (19.6 kD), and differs just in the 3 first amino acids in the
amino side from the TRAIL domain of Fn14•TRAIL. sFN14 (5.6
kD), is composed of the 53 amino acids of the extracellular
domain of Fn14, and differs from the Fn14 part of Fn14•TRAIL
by one amino acid, the first from the carboxy-side. Fn14•TRAIL
molecular weight is calculated to be 24.6 kD. As shown in
Figure 5, Fn14•TRAIL was substantially more efficient in
inducing HCC cell death when compared not only to sTrail and
Fn14-Fc, but also to a combination of the two. Of note, we
repeated this set of experiments with soluble Fn14, instead of
Fn14-Fc, as the later is a dimer and does not tend to form
trimers as TNF-family proteins do, and the results were the
same. Importantly, although comparison was made for the
same dose of proteins, Fn14•TRAIL's molecular weight is
heavier than that of sTRAIL or sFn14, and therefore there was
actually more of the other proteins if the molar amount is
considered, making the difference in efficacy more significant.
Fn14*TRAIL Inhibits HCC Growth in Xenograft Model
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Figure 3.  Fn14•TRAIL induces apoptosis of HCC cell lines.  (A-C) SK-HEP-1 [A, and B upper panel], HepG2 [B, middle panel]
and Huh7 [B, lower panel] HCC cell lines, as well as NKNT3 [C, upper panel] and FHB [C, lower panel] hepatocyte cell lines, were
incubated with indicated concentrations of Fn14•TRAIL for 24 hours. Treated cells were stained by Annexin V-FITC and Propidium
Iodide, and counted by flow cytometer (20,000 cells per sample). (A) A representative experiment, (B,C) - Results represent the
mean +/- SE of 3 independent experiments (* p < 0.05 vs no Fn14•TRAIL). (D) HepG2 cells were incubated with Fn14•TRAIL for
indicated time periods, whole cells lysats were immunoblotted with the indicated Abs. This is a representative out of 3 independent
experiments. (E). HepG2 cells were incubated with Fn14•TRAIL for indicated time periods. Whole cells lysats were immunoblotted
with the indicated Abs. (F). HepG2 cells were incubated with Fn14•TRAIL for indicated time periods. Whole cells lysats were
immunoblotted with the indicated Abs. This is the summery of 3 independent experiment. The results represent the mean +/- SD of
triplicates (* p ≤ 0.05).
doi: 10.1371/journal.pone.0077050.g003
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Figure 4.  HCC and hepatocyte cell lines express TRAIL, TRAIL receptors, Fn14 and TWEAK.  (A) The mRNA expression level
of TRAIL, TRAIL receptors (DR4, DR5, DCR-1, DCR-2, OPG), Fn14 and TWEAK was determined by quantitive real-time PCR
analysis. A representative experiment of three independent experiments is shown. Data are shown as average of triplicates (SD <
0.3), normalized against two endogenous control human genes, TBP and Actin-B, as calculated by Dataassist v2.0 software. (B,C)
Protein expression of TRAIL, TRAIL receptors (DR4, DR5, DcR1, DcR2), Fn14 and TWEAK was determined by flow cytometeric
analysis. (D) Fn14•TRAIL binds to HCC cells – HepG2 cells were incubated with Fn14•TRAIL, soluble TRAIL, Fn14 or the
combination of the latter for 30 min at 4°c, immune-stained with PE-conjugated anti-Fn14, and analyzed by flow-cytometry. The
results represent the mean +/- SD of triplicates (* p ≤ 0.05).
doi: 10.1371/journal.pone.0077050.g004
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Fn14•TRAIL's activity can be blocked using anti-TRAIL
and anti-Fn14 Ab
To investigate the importance of the Fn14•TRAIL fusion
protein’s two ends, we turned to Ab blocking. Specifically, we
incubated the HCC cell lines with Fn14•TRAIL in the presence
or absence of anti-TRAIL or anti-Fn14 Ab for 24h, and
assessed apoptosis by Annexine/PI staining and flow
cytometry. Significantly, both anti-TRAIL and anti-Fn14 Ab
completely abrogated the apoptosis induced by Fn14•TRAIL
(Figure 5B), indicating that both molecular domains of the
fusion protein are critical for its activity.
Fn14•TRAIL inhibits tumor growth in vivo
We next moved in vivo, examining Fn14•TRAIL's ability to
inhibit tumor growth. NUDE mice were injected subcutaneously
with HepG2 cells and followed daily for tumor growth. When
tumors were palpable in individual mice, they were treated with
either Fn14•TRAIL (200 µg/day) or vehicle, both administered
subcutaneously once daily, for 8 consecutive days. Starting on
day 2 after the initiation of treatment, a clear difference in tumor
growth rate became apparent, with tumors in the Fn14•TRAIL
treatment group growing slower or even decreasing in size
(Figure 6A,B). Interestingly, the inhibitory effect on tumor
growth persisted for at least 2-3 weeks after the 8 day
treatment window. Tumors were excised and weighed at the
end. The weights of excised tumors were consistent with the
Figure 5.  Fn14•TRAIL is more potent than soluble forms of Trail and Fn14 alone or in combination.  (A) SK-HEP-1 [A, left
panel], HepG2 [A, middle panel] and Huh7 [A, right panel] HCC cell lines, as well as NKNT3 [B, left panel] and FHB [B, right panel]
hepatocyte cell lines, were incubated with 0, 3, 30 or 300 ng/ml of Fn14•TRAIL, TRAIL, Fn14-Fc or combination of the later two for
48 hours. Viable cells were stained with trypan blue and counted. The results represent the mean +/- SD of three independent
experiments (* p ≤ 0.05). (B) HepG2 HCC cells were incubated with 30ng/ml Fn14•TRAIL for 24 hours, in the presence or absence
of anti Fn14 or anti TRAIL blocking antibodies. Treated cells were stained by Annexin V-FITC and Propidium Iodide, and counted by
flow cytometer (2x104 cells per sample). The results represent the mean +/- SD of two independent experiments (* p ≤ 0.05).
doi: 10.1371/journal.pone.0077050.g005
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external measurements. In order to verify that Fn14•TRAIL
induces apoptosis in vivo, in a different experiment, tumors
from Fn14•TRAIL treated mice or vehicle treated mice were
excised after two doses of treatment and were immuno-stained
against cleaved caspase 3. Tumors taken from Fn14•TRAIL
treated mice were stained positively, indicating that cells are
undergoing apoptosis (Figure 6C).
Importantly, no morbidity, liver or renal toxicity were
observed in the Fn14•TRAIL-treated mice based upon liver
enzymes, histopathological examination and urea
measurments as can be seen in Figure 7.
Discussion
In the present study, we explored Fn14•TRAIL’s unique
properties as an anti-tumor agent. Main findings are: 1)
Fn14•TRAIL strongly induces apoptosis in three different HCC
cell lines; 2) While HCC cell lines express DR4, DR5 and Fn14
on their surfaces, substantial TWEAK is detected only
intracellulary; 3) Non-malignant hepatocyte lines are insensitive
to Fn14•TRAIL-induced apoptosis, notwithstanding their similar
expression of the aforementioned molecules; 4) Fn14•TRAIL is
significantly more effective than soluble Trail, Fn14-Fc or a
combination of the two in inducing apoptosis; 5) Fn14•TRAIL's
activity can be blocked by Ab directed against TRAIL and
Fn14; 6) Fn14•TRAIL effectively inhibits the growth of HCC
xenograft tumors in nude mice; and 7) Fn14•TRAIL is well
tolerated by mice, with no detectable changes in liver histology.
Taken together, these findings establish Fn14•TRAIL’s
potential as anti-tumor agent, extending its therapeutic
possibilities beyond treatment of autoimmunity.
Soluble TRAIL has been considered for some time now for
its potential as a cancer therapeutic [23–25]. However, some
malignant tumors are known to be resistant to the pro-apoptotic
effect of soluble TRAIL. While recombinant TRAIL variants, as
well as agonist Ab with specificity for the TRAIL receptors DR4
and DR5, were used for inhibiting the growth of various types
of malignant cells both in vitro and in vivo [26–29], others,
found the same HCC cell lines under study here, (SK-HEP-1,
HepG2 and Huh7), to be highly resistant to TRAIL-induced
Figure 6.  Fn14•TRAIL inhibits tumor growth in-vivo.  HepG2 cells were injected subcutaneously (4-5x106/mouse) to NUDE
mice. Mice were treated daily with subcutaneous injections of Fn14•TRAIL (200μg) or vehicle for 8 days. Tumor volume was
followed in two independent experiments, for 16 days (A) or 34 days (B). The results represent the average volume of tumors,
measured for five Fn14•TRAIL treated animals and four controls (A), and of eight Fn14•TRAIL treated animals and seven controls
(B), +/- SD, (* p ≤ 0.05) (C) HepG2 cells were injected subcutaneously (4-5x106/mouse) to NUDE mice. Mice were treated with
subcutaneous injections of Fn14•TRAIL (200μg) or vehicle for 2 days. Tumors were excised one hour after the second injection.
Immunostaining was performed with anti activated caspase 3 Abs.
doi: 10.1371/journal.pone.0077050.g006
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apoptosis [30,31]. This resistance was notwithstanding their
expression of DR4 and DR5. Our observation that Fn14•TRAIL,
a fusion protein derivative of this same protein, engenders
robust apoptosis of the same malignant cells at extremely low
concentrations (less than 3 ng/ml in the case of SK-HEP-1
cells) is especially notable.
The basis for Fn14•TRAIL’s enhanced pro-apoptotic activity
may be several-fold. One possibility is that it stems from the
synergy attained by virtue of coordinate blocking of the TWEAK
ligand and triggering of TRAIL receptors. However, our
repeated observation that the fusion protein is consistently
more effective than its soluble components (Fn14 and TRAIL)
in combination suggests that there may be yet other
explanations for Fn14•TRAIL’s superior activity. One of these
explanations revolves around molecular structure, with the
possibility that Fn14•TRAIL assumes a higher-order
configuration that allows it to function as ’super-TRAIL’. For
instance, this could result from stabilization of the TRAIL trimer
via TWEAK-induced trimerization of the Fn14 end. TRAIL and
other members of the TNF receptor family were shown to be
more potent in the trimer form (18-20).
The Ab-blocking experiments of the present study shed
some light on these mechanistic possibilities. Anti-Fn14 Ab
completely abrogated Fn14•TRAIL's pro-apoptotic activity.
Possible explanation for this key observation is that the Ab
interferes with Fn14’s binding to TWEAK, which in turn could
impact both higher order structure of the chimeric protein
and/or molecular arraying and signaling at the cell surface.
The variable sensitivity of HCC cell lines to Fn14•TRAIL’s
pro-apoptotic activity is of interest. However, we could not
correlate this differential sensitivity with the protein and mRNA
levels of TRAIL receptors, TRAIL, Fn14 and TWEAK in the
targeted tumor cells. This is in agreement with previous reports
indicating that wide range of tumors express TRAIL receptors,
Figure 7.  No hepatotoxicty is observed in Fn14•TRAIL treated mice.  HepG2 Nude mice were treated daily with subcutaneous
injections of 200μg of Fn14•TRAIL (n=4) or vehicle (n=4) for 8 days. One hour after last injection blood counts (A) liver enzymes
and urea (B) were measured. Livers were harvested and H&E stained sections were tested (C). Data are presented as mean +/-
S.E.
doi: 10.1371/journal.pone.0077050.g007
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but these are not correlated with sensitivity to TRAIL–induced
apoptosis [11,32,33], and post translation modifications of the
receptors, influencing their activity has been proposed to
explain this phenomena. We did observe that those HCC cells
more sensitive to soluble TRAIL tended to be more sensitive to
Fn14•TRAIL. Looking at the intracellular signaling pathways,
we found that decreased expression of anti-apoptotic signals in
parallel with activation of the pro-apoptotic ones was
associated with higher sensitivity to Fn14•TRAIL. Decreased
expression of the anti-apoptotic signals was not observed in
non-malignant cells.
The role of TWEAK in this system remains somewhat
enigmatic. Whereas surface TWEAK could not be readily
detected by immunofluorescence, this protein was readily
detectable intracellularly and in conditioned medium. We could
not show effect of Fn14•TRAIL on TWEAK:Fn14 signaling
pathway in this study. However, most studies unfolding the
signaling pathways involved in the Fn14:TWEAK axis were
performed with recombinant TWEAK added to the experimental
setting [34,35], and this is not the case in our study. TWEAK
independent Fn14 signaling have been implicated in some
tissues [36], however, it has not been described in HCC cell
lines, and therefore it is not expected that Fn14•TRAIL will
influence this signaling pathway.
There is no consensus as to whether it is more beneficial to
block as opposed to activate the TWEAK: Fn14 signaling axis
in the context of cancer therapeutics. Arguing for blockade are
studies indicating the importance of TWEAK in tumor cell
survival, resistance to apoptosis and migration [7,8,34,37–39].
Also pointing in this direction is the demonstration that enforced
TWEAK over-expression enhances proliferation in vivo [40].
This view is consistent with our suggestion of using
Fn14•TRAIL as a TWEAK blocker.
On the other hand, there is data in the literature arguing in
the other direction, for a potential benefit in activating this
pathway. These data encompass findings that TWEAK itself
possesses pro-apoptotic activity, either directly through
activation of the caspase cascade [41,42], or indirectly via
inducing TNF-alpha [35]. The indirect mechanism parallels that
associated with other death domain-deficient receptors, such
as CD30 and CD40 [43,44] . Also, a recent study has shown
that agonistic anti-Fn14 Ab has anti-tumor activity, both in vitro
and in vivo [42]. However, caution is called for in interpreting
the latter findings given that, as the authors themselves point
out, at least some of anti-tumor activity of the agonistic anti-
Fn14 Ab, was mediated by antibody-dependent cell
cytotoxicity.
Recently, we reported two other fusion proteins,
CTLA-4•FasL and CD40•FasL, with cytotoxic activity against
tumor cells [20]. Interestingly, we demonstrated that these
proteins function, at least in part, by bridging neighboring
molecules on tumor cell surfaces [20,45]. Whether Fn14•TRAIL
shares mechanistic features with these other fusion proteins
(for example, Fn14 binding to a surface molecule other than
TWEAK, or to sub-threshold levels of TWEAK) remains to be
determined. However, regardless of how this unfolds, the
broader concept that fusion proteins with more than one
functional component can be used for tumor cell targeting is
now being reinforced, and in this way, opens up a new avenue
for devising therapeutics that fit into the personalized onco-
medicine paradigm.
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